Highly sensitive in vitro cytokine release assay incorporating high-density preculture.

IF 2.4 4区 医学 Q3 TOXICOLOGY
Shiho Ito, Kyoko Miwa, Chiharu Hattori, Tetsuo Aida, Yoshimi Tsuchiya, Kazuhiko Mori
{"title":"Highly sensitive <i>in vitro</i> cytokine release assay incorporating high-density preculture.","authors":"Shiho Ito,&nbsp;Kyoko Miwa,&nbsp;Chiharu Hattori,&nbsp;Tetsuo Aida,&nbsp;Yoshimi Tsuchiya,&nbsp;Kazuhiko Mori","doi":"10.1080/1547691X.2021.1984617","DOIUrl":null,"url":null,"abstract":"<p><p>Immunostimulatory effects of monoclonal antibodies (mAb) through binding to F<sub>cγ</sub> receptors (F<sub>cγ</sub>R) on immune cells are a likely cause of cytokine release syndrome. However, it is difficult to detect the potential risk of F<sub>cγ</sub>R-dependent cytokine release associated with mAb in the current standard cytokine release assays (CRA), including the air-drying solid-phase method using human peripheral blood mononuclear cells (PBMC). To increase the sensitivity to detect F<sub>cγ</sub>R-dependent cytokine release due to mAb, a high-density preculture (HDC) method was incorporated into the air-drying solid-phase CRA. Here, PBMC were exposed to panitumumab, trastuzumab, rituximab, or alemtuzumab at 0.1, 0.3, 1, and 3 μg/well for 24 or 48 hr under both non-HDC and HDC conditions. T-cell agonists (anti-CD3 mAb, anti-CD28 super-agonist [SA] mAb) were used as reference mAb. Panitumumab, trastuzumab, rituximab, or alemtuzumab induced cytokine release under both non-HDC and HDC conditions, and cytokine release caused by alemtuzumab was more pronounced under HDC conditions. To investigate F<sub>cγ</sub>R involvement in cytokine release associated with panitumumab, trastuzumab, rituximab, and alemtuzumab, CRA of these four mAb were conducted with anti-F<sub>cγ</sub>RI, -F<sub>cγ</sub>RII, or -F<sub>cγ</sub>RIII F(ab')<sub>2</sub> fragments. The results showed cytokine release caused by trastuzumab, rituximab, and alemtuzumab was significantly suppressed by anti-F<sub>cγ</sub>RIII F(ab')<sub>2</sub> pretreatment, and slightly reduced by anti-F<sub>cγ</sub>RI or anti-F<sub>cγ</sub>RII pretreatment, indicating these mAb induced F<sub>cγ</sub>R (especially F<sub>cγ</sub>RIII)-dependent cytokine release from PBMC. Cytokine release caused by panitumumab was slightly suppressed by anti-F<sub>cγ</sub>RIII F(ab')<sub>2</sub> pretreatment. Anti-CD3 mAb and anti-CD28 SA mAb also induced significant release of cytokines under HDC conditions compared with that under non-HDC conditions. In conclusion, CRA incorporating HDC into the air-drying solid-phase method using human PBMC could sensitively capture the F<sub>cγ</sub>R-dependent cytokine release potential of mAb.</p>","PeriodicalId":16073,"journal":{"name":"Journal of Immunotoxicology","volume":" ","pages":"136-143"},"PeriodicalIF":2.4000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Immunotoxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1547691X.2021.1984617","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"TOXICOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Immunostimulatory effects of monoclonal antibodies (mAb) through binding to F receptors (FR) on immune cells are a likely cause of cytokine release syndrome. However, it is difficult to detect the potential risk of FR-dependent cytokine release associated with mAb in the current standard cytokine release assays (CRA), including the air-drying solid-phase method using human peripheral blood mononuclear cells (PBMC). To increase the sensitivity to detect FR-dependent cytokine release due to mAb, a high-density preculture (HDC) method was incorporated into the air-drying solid-phase CRA. Here, PBMC were exposed to panitumumab, trastuzumab, rituximab, or alemtuzumab at 0.1, 0.3, 1, and 3 μg/well for 24 or 48 hr under both non-HDC and HDC conditions. T-cell agonists (anti-CD3 mAb, anti-CD28 super-agonist [SA] mAb) were used as reference mAb. Panitumumab, trastuzumab, rituximab, or alemtuzumab induced cytokine release under both non-HDC and HDC conditions, and cytokine release caused by alemtuzumab was more pronounced under HDC conditions. To investigate FR involvement in cytokine release associated with panitumumab, trastuzumab, rituximab, and alemtuzumab, CRA of these four mAb were conducted with anti-FRI, -FRII, or -FRIII F(ab')2 fragments. The results showed cytokine release caused by trastuzumab, rituximab, and alemtuzumab was significantly suppressed by anti-FRIII F(ab')2 pretreatment, and slightly reduced by anti-FRI or anti-FRII pretreatment, indicating these mAb induced FR (especially FRIII)-dependent cytokine release from PBMC. Cytokine release caused by panitumumab was slightly suppressed by anti-FRIII F(ab')2 pretreatment. Anti-CD3 mAb and anti-CD28 SA mAb also induced significant release of cytokines under HDC conditions compared with that under non-HDC conditions. In conclusion, CRA incorporating HDC into the air-drying solid-phase method using human PBMC could sensitively capture the FR-dependent cytokine release potential of mAb.

采用高密度预培养的高灵敏度体外细胞因子释放试验。
单克隆抗体(mAb)通过与免疫细胞的Fcγ受体(Fcγ r)结合产生免疫刺激作用,可能是细胞因子释放综合征的原因之一。然而,在目前的标准细胞因子释放试验(CRA)中,包括使用人外周血单个核细胞(PBMC)的空气干燥固相法,很难检测到与单抗相关的fc γ r依赖性细胞因子释放的潜在风险。为了提高检测单克隆抗体引起的fc γ r依赖性细胞因子释放的灵敏度,将高密度预培养(HDC)方法加入到风干固相CRA中。在非HDC和HDC条件下,PBMC分别以0.1、0.3、1和3 μg/孔暴露于帕尼单抗、曲妥珠单抗、利妥昔单抗或阿仑单抗24或48小时。t细胞激动剂(抗cd3单抗、抗cd28超级激动剂[SA]单抗)作为参考单抗。帕尼单抗、曲妥珠单抗、利妥昔单抗和阿仑单抗在非HDC和HDC条件下均能诱导细胞因子释放,且阿仑单抗在HDC条件下引起的细胞因子释放更为明显。为了研究FcγR与帕尼单抗、曲妥珠单抗、利妥昔单抗和阿仑单抗相关的细胞因子释放的关系,我们用抗fc γ ri、-FcγRII或-FcγRIII F(ab’)2片段对这四种单抗进行CRA。结果显示,抗FcγRIII F(ab’)2预处理显著抑制曲妥珠单抗、利妥昔单抗和阿仑单抗引起的细胞因子释放,而抗fc γ ri或抗fc γ rii预处理引起的细胞因子释放略有降低,说明这些单抗可诱导FcγR(尤其是FcγRIII)依赖性细胞因子从PBMC释放。抗fc - γ riii F(ab’)2预处理可轻微抑制帕尼单抗引起的细胞因子释放。与非HDC条件相比,Anti-CD3 mAb和anti-CD28 SA mAb在HDC条件下也能诱导细胞因子的显著释放。综上所述,利用人PBMC将HDC纳入空气干燥固相法的CRA可以灵敏地捕获单抗的fc γ r依赖性细胞因子释放电位。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Immunotoxicology
Journal of Immunotoxicology 医学-毒理学
CiteScore
6.70
自引率
3.00%
发文量
26
审稿时长
1 months
期刊介绍: The Journal of Immunotoxicology is an open access, peer-reviewed journal that provides a needed singular forum for the international community of immunotoxicologists, immunologists, and toxicologists working in academia, government, consulting, and industry to both publish their original research and be made aware of the research findings of their colleagues in a timely manner. Research from many subdisciplines are presented in the journal, including the areas of molecular, developmental, pulmonary, regulatory, nutritional, mechanistic, wildlife, and environmental immunotoxicology, immunology, and toxicology. Original research articles as well as timely comprehensive reviews are published.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信